Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine add-on therapy to clozapine in refractory schizophrenia
NL-OMON39302Phase 2Active, not recruiting
- Sponsor
- GGZ Noord-Holland Noord
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of memantine in schizophrenia (2 arms), sponsored by GGZ Noord-Holland Noord. Primary endpoints: Cognitive functioning, Clinical Global Impression Severity Scale and 2 more. Started Aug 2013; status: active, not recruiting.
02
Drugs
memantine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NL-OMON39302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39302.